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Rabies virus (RV) deficient in the P gene was generated by reverse genetics from cDNA of HEP-Flury strain lacking the entire P gene.
The defective virus was propagated and amplified by rescue of virus, using a cell line that complemented the functions of the deficient gene.
The P gene-deficient (def-P) virus replicated its genome and produced progeny viruses in the cell lines that constitutively expressed the P
protein, although it grew at a slightly retarded rate compared to the parental strain. In contrast, no progeny virus was produced in the infected
host when the def-P virus-infected cells that did not express the P protein. However, we found that the def-P virus had the ability to perform
primary transcription (by the virion-associated polymerase) in the infected host without de novo P protein synthesis. The def-P virus was
apathogenic in adult and suckling mice, even when inoculated intracranially. Inoculation of def-P virus in mice induced high levels of virus-
neutralizing antibody (VNA) and conferred protective immunity against a lethal rabies infection. These results demonstrate the potential
utility of gene-deficient virus as a novel live attenuated rabies vaccine.
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Rabies virus (RV) belongs to the genus Lyssavirus of the
family Rhabdoviridae. Its genome is nonsegmented nega-
tive-strand RNA encoding five structural proteins: nucleo-
protein (N), phosphoprotein (P), matrix protein (M),
glycoprotein (G), and large protein (L) (Dietzshold et al.,
1996; Wagner and Rose, 1996). The viral RNA polymerase
is composed of L and P protein: the L protein is the major
catalytic component, and the P protein is a noncatalytic
cofactor (Chenik et al., 1998; Schnell and Conzelmann,
1995). The P protein exhibits several phosphorylation states,
consequently binding to the ribonucleocapsid with several
different affinities; in this way, transcription and replication
are regulated (Fu et al., 1994; Jacob et al., 2001; Takamatsu
et al., 1998). The P protein also interacts with cytoplasmic0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: kmorimot@nih.go.jp (K. Morimoto).dynein light chain (LC8), suggesting that it is involved in
retrograde axonal transport of RV (Jacob et al., 2000; Raux
et al., 2000). Recently, it was demonstrated that interaction
of P protein with LC8 was necessary for spread of RV from
a peripheral site to the central nervous system, in experi-
ments using reverse genetics (Mebatsion, 2001).
Reverse genetics with negative-strand RNA virus has
facilitated manipulation of genome composition (Schnell et
al., 1994). Reverse genetics has been used with several
negative-strand RNA viruses to elucidate functions of viral
proteins and develop live attenuated vaccines or viral vectors
(Conzelmann, 1998; Neumann et al., 2002). RV- and vesic-
ular stomatitis virus-based vectors have been developed as
vaccine vehicles expressing foreign viral proteins; for ex-
ample, human immunodeficiency virus type 1 (HIV-1) Gag,
HIV-1 Env, or influenza virus HA protein. Experimental
vaccines using such vehicles have been found to be highly
effective (Haglund et al., 2002; McGettigan et al., 2003;
Reuter et al., 2002; Roberts et al., 1999). Furthermore,
rearrangement of the gene order of vesicular stomatitis virus
provides a new approach to generation of live attenuated
vaccines (Flanagan et al., 2000, 2001). Influenza A virus
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defective F gene have been generated using reverse genetics.
Gene-deficient viruses are potentially useful as virus vectors
or live attenuated vaccines (Li et al., 2000; Watanabe et al.,
2001, 2002a, 2002b). Defective RV mutants lacking the G or
M gene have been generated and have been used to charac-
terize assembly and budding of viral particles (Mebatsion et
al., 1996, 1999). However, there have been no reports of use
of such particles in a live vaccine.
In the present study, we generated P gene-deficient RV
virus using an improved method for recovery of RV from
cloned DNA, in which method RNA polymerase II drove
the transcription (Inoue et al., 2003a). The rescue of the P
gene-deficient virus was performed using cell lines that
constitutively express the P protein. This protocol resulted
in efficient production and propagation of the P gene-
deficient RV virus. The P gene-deficient viruses can grow
in an environment supplying P protein, and they can infect
cells susceptible to wild-type RV infection. We speculate
that expression of viral proteins follows primary viral
transcription in cells infected with the P gene-deficient
virus. The present findings suggest that the P gene-deficientFig. 1. (A) Construction of the P gene-deficient RV cDNA plasmid. The cDNA
contains five viral genes), was cut with AvrII and BlpI restriction enzymes. A 2.2-
new 1.2-kb AvrII-BlpI fragment (containing only N gene region) was obtained by P
introduced behind the stop codon of N gene). The 1.2-kb AvrII-BlpI fragment was i
cDNA plasmid p3.1-defP (bottom). Open box, gene junction; shaded box (N, P, an
HEP-Flury antigenomic sequence (GenBank AB085828). (B) The nucleotide seq
virus. UAA, stop codon of N or P gene; GCUAAGCA, BlpI restriction site; AAAA
type. The putative transcribed nucleotides were underlined.virus is a promising safe live vaccine and may be useful for
development of a safe viral vector.Results
Construction of P gene-deficient cDNA plasmid and
recovery of P gene-deficient virus
To generate P gene-deficient RV virus by reverse genet-
ics, we constructed a cDNA plasmid in which the entire P
gene was deleted. The coding region of the P protein was
deleted from the full-length cDNA plasmid (pHEP-3.0) of
HEP-Flury strain, as shown in Fig. 1. The cells were trans-
fected with the P gene-deficient plasmid p3.1-defP, together
with helper plasmids containing genes for viral N, P, or L
protein (to support viral RNA transcription and replication),
to generate P gene-deficient virus particles (def-P virus)
using two different procedures: (1) transfection of BHK cells
with p3.1-defP and three helper plasmids (pH-N, pH-P, and
pH-L); (2) transfection of BHK-P or NA-P cells that consti-
tutively express the P protein (Figs. 2B, D) with p3.1-defP,plasmid pHEP-3.0 (top), containing the entire HEP-Flury genome (which
kb AvrII-BlpI fragment (containing N and P gene regions) was removed. A
CR amplification with H-Avr5 primer and Nstop-Blp3 primer (BlpI site was
nserted into AvrII and BlpI sites of pHEP-3.0, producing the P gene-deficient
d M), viral gene-encoding region. Numbers refer to nucleotide positions of
uence (antigenomic sense) across the deleted region of the P gene-deficient
AAA, poly(A) signal; and AUG, start codon of M gene were shown in bold
Fig. 2. Expression of P protein in NA-P and BHK-P cells and expression of
N protein in def-P virus-infected cells. (I) NA, BHK, and cell lines
constitutively expressing P protein (NA-P and BHK-P) were fixed with
80% acetone. Expression of P protein was determined by indirect
immunofluorescent staining using rabbit anti-P antiserum and FITC-
conjugated anti-rabbit antibody. Evans Blue was used as a counter-stain
(red color). (A) NA, (B) NA-P, (C) BHK, and (D) BHK-P cells. (II)
Immunoblot analysis of P protein in NA-P cells. Aliquots of cell-lysate with
equal cell numbers were subjected to SDS-PAGE and immunoblotting.
Lanes 1, NA-P cells; 2, NA cells; 3, rHEP virus-infected NA cells; Lane M,
protein molecular marker: ovalbumin (45 kDa) and carbonic anhydrase (30
kDa). (III) NA and NA-P cells were infected with def-P virus at a MOI of
0.1, and fixed with 80% acetone at day 3 after the infection. Expression of
viral N protein was examined by immunostaining with FITC-conjugated
anti-N antibody. (E) def-P virus-infected NA-P, (F) mock-infected NA-P,
(G) def-P virus-infected NA, and (H) mock-infected NA.
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of these procedures (data not shown). In order to achieve
high-level recovery of the def-P virus, BHK-P cells were
transfected with p3.1-defP, pH-N, pH-L, pH-P, and pH-G, as
described in Materials and methods. This procedure pro-
duced high levels of the def-P virus. Simultaneous transient
and constitutive expression of the P protein promoted
generation and propagation of the def-P virus. Inoculation
of BHK-P or NA-P cells with the culture supernatant of the
transfected cells resulted in further virus amplification.
Stable transfectants with the plasmid, pH-P, were cloned
and examined for the expression of the P protein by
immunofluorescent microscopy. Fig. 2I shows the represen-
tative results of the P protein expression in the cell lines. In
the BHK-P cells, although the expression of the P protein in
the individual cells was lower than that in the NA-P cells,
fluorescent signals were observed in around 80% of the total
cell population (Fig. 2D). In the NA-P cells, stronger P
protein signals were found in limited numbers (around 35%)
of the total cell population (Fig. 2B). The total expression of
P protein in the cell line was 7% of that in virus-infected cell
culture (Fig. 2II).
Infection of these cell lines with the def-P virus was
monitored by immunofluorescence staining of viral N protein
(Fig. 2III). Abundant expression of the N protein was seen in
the NA-P cells, indicating the def-P virus-infected and
expressed viral proteins well in the cell line (Fig. 2E). These
findings indicate that a supply of P protein in the host cell was
necessary for propagation of the def-P virus. The N protein
was weakly expressed in NA cells infected with the def-P
virus (Fig. 2G). In cells not expressing P protein, it is likely
that only primary transcription was achieved by the viral
polymerase (which was associated with the ribonucleocapsid
of the def-P virus), and that secondary transcription and
genome replication were impaired, probably due to the
absence of newly synthesized P protein (data described
below).
Characterization of P gene-deficient virus in vitro
To examine the growth characteristics of the def-P virus,
the expression of viral N protein was monitored in the BHK-
P and BHK cells infected with the def-P virus at a multi-
plicity of infection (MOI) of 0.1 FFU/cell during the course
of infection (Fig. 3I). One day after infection of BHK-P cells,
fluorescent signals of the N protein were clearly detected in
several cells, and the foci apparently continued to increase
and spread to adjacent cells on days 2 and 3 (Fig. 3I, left
panels). At day 3 postinfection, there were still some
noninfected cells because of low MOI, retarded growth of
def-P, and existence of P protein non-expressing cells. In
contrast, the def-P virus exhibited poor replicative efficacy in
the BHK cells; the expression of N protein was extremely
low (Fig. 3I, right panels). The growth kinetics of the def-P
virus in the BHK-P and BHK cells was examined in the
experiments shown in Figs. 4A, B. The cells were infected
Fig. 3. (I) Propagation of def-P virus in BHK-P (constitutively expressing P
protein, left panels) and BHK (right panels) cells. The def-P virus-infected
BHK-P and BHK cells were fixed at day 1 (A, D), day 2 (B, E) and day 3
(C, F) after the infection (MOI = 0.1) and were subjected to immuno-
fluorescent staining with FITC-conjugated anti-N antibody. White arrow
indicates faint fluorescence seen in the def-P virus-infected BHK cells at
day 3. Evans Blue was used as a counter stain (red color). (II) Expression of
N protein in def-P virus-infected BHK-P and BHK cells. The virus-infected
cells (MOI = 10) were lysed at day 3 postinfection. The aliquots of the
infected cell-lysate were subjected to SDS-PAGE and immunoblot against
N protein. Lanes 1, rHEP infected BHK; 2, def-P infected BHK-P; 3, def-P
infected BHK; 4, mock-infected BHK-P. The loaded cell-lysate was equal
to 2  103 cells in lane 1; 4  104 cells in lanes 2, 3, and 4.
Fig. 4. Growth curve of rHEP and def-P virus in BHK-P (A) and BHK (B)
cells. Cells were infected with rHEP or def-P virus at a MOI of 10 and
incubated at 37 jC. The viruses were harvested on day 0, 1, 2, 3, and 4 after
the infection. Serial dilutions of the harvested virus suspensions were used to
infect monolayers of BHK-P cells in a 96-well plate. Titration of the virus
was determined by counting the foci using immunofluorescence staining.
Triangle, rHEP; circle, def-P. (C) Virus production in passages of def-P-
infected BHK-P cell culture. The def-P virus-infected BHK-P cells were
maintained for several passages. The cell culture was split twice a week. At
each passage, the culture supernatant was collected for virus titration.
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10, and the culture supernatants were harvested every 24
h until day 4 after the infection. Titers of the progeny viruses
were determined using monolayers of the BHK-P cells. The
parental rHEP strain exhibited productive replication in both
BHK-P and BHK cells, and grew to a titer of over 108 FFU/
ml. In the BHK-P cells, the def-P produced progeny viruses,
although the growth of def-P virus was slightly retarded. Atall time points, production of the def-P virus in the BHK-P
cells was moderate, compared with production of the rHEP
virus (Fig. 4A). This may be due to reduction of viral
polymerase replication activity to less than full capacity,
resulting from insufficient levels of the P protein.
When cells not expressing the P protein were infected with
def-P virus, almost no progeny virus was released into the
culture supernatant (Fig. 4B), but viral protein was weakly
but clearly produced (Figs. 2G, 3F). This indicates that the
def-P virus was able to express a small amount of viral
protein. The expression of N protein in the def-P virus-
infected BHK cells was detected by immunoblot analysis.
Fig. 5. RT-PCR of viral transcripts in def-P virus-infected BHK and BHK-P
cells. Total RNA was extracted from BHK and BHK-P cells infected with
def-P virus, and messenger RNA for viral N, P, G, and GAPDH were
amplified by RT-PCR, using primer sets described in Materials and
methods. The RT-PCR products were electrophoresed through a 1.5%
agarose gel. (A) Lanes 1 and 5, N gene: 684 bp; lanes 2 and 6, P gene: 882
bp; lanes 3 and 7, G gene: 816 bp; lanes 4 and 8, GAPDH gene: 348 bp; M,
molecular size marker. (B) Lanes 1 and 3, GAPDH gene; lanes 2 and 4,
intergene product: 972 bp. (C) Lanes 1 and 5, N gene; lanes 2 and 6, P
gene; lanes 3 and 7, G gene; lanes 4 and 8, GAPDH gene. The amount of
purified GAPDH product was determined by UV absorption of OD260. To
compare amounts of viral N, P, and G products, the loaded volume of PCR
products in each preparation was adjusted depending on the amount of
GAPDH product. The PCR amplifications were carried out for 30 cycles
(A, B) and 20 cycles (C).
Fig. 6. Apathogenicity of P gene-deficient virus (def-P). ICR suckling mice
were inoculated intracranially with 2  102 FFU (closed triangle) or 2 
103 FFU (closed circle) of rHEP strain, or 2  103 FFU (open triangle) or
2  104 FFU (open circle) of def-P virus. Groups of 10 mice were
inoculated with virus suspension and observed for 2 weeks for clinical
signs of rabies.
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less than that in the infected BHK-P cells (Fig. 3II). To
support the evidence of the viral protein expression, the
presence of viral transcripts in the def-P virus-infected cells
was examined by analyzing messenger RNA with RT-PCR
(Fig. 5A). In the def-P virus-infected BHK cells, transcripts of
the viral N and G genes were detected, but at much lower
levels than in the BHK-P cells. As expected, no P gene
transcripts were detected (Fig. 5A, lane 2). To eliminate the
possibility that the PCR products were derived from genomic
sense in the RT-preparation, the intergenic region between N
and M genes were amplified (Fig. 5B). The 972-base PCR
product was not detected in the RT-preparation. These results
indicate that the virion-associated RNA polymerase complex
of the def-P virus performed primary transcription without de
novo P protein synthesis.
On the other hand, in the BHK-P cells infected with the
def-P virus, transcripts of the N, P, and G genes were
detected. The P gene transcripts were derived from the Pgene that had been integrated in the host cells (Fig. 5A, lane
6). The levels of N and G transcripts matched that of the
host-derived P transcript (Fig. 5A, lanes 5, 6, 7). The levels
of viral transcripts were compared between def-P virus-
infected BHK-P cells and rHEP virus-infected cells. The
PCR amplification was performed for 20 cycles to avoid
saturation of the PCR products (Fig. 5C). The amounts of
viral transcripts in def-P virus-infected cells were less than
10% of those in rHEP virus-infected cells (N, 8.3%; P,
7.1%; G, 9.8%). This indicates that the viral transcription
activity depends on the level of P transcript (or P protein) in
the cells expressing P protein.
Fig. 4A shows that production of progeny viruses in the
def-P virus-infected BHK-P cells were slower than in the
rHEP virus-infected cells. A lower degree of cytotoxicity
was observed in the def-P virus-infected BHK-P cells than
in the rHEP-infected cells. These findings prompted us to
assess survival of cell cultures after RV infection. The def-P
virus-infected culture was split twice a week, and survived
for longer than 1 month, whereas the rHEP virus-infected
cultures had died by the fourth passage. Production of def-P
virus was assessed by examining culture supernatant at each
passage (Fig. 4C). The highest titer (108 FFU/ml) was
obtained at the fourth passage. A virus titer greater than
107 FFU/ml was detected in the persistently infected cul-
tures until the fifth passage, with virus release gradually
decreasing thereafter. The BHK-P cells infected with the
def-P virus can be maintained for several passages because
of the retarded growth of def-P virus.
Pathogenicity of P gene-deficient virus
HEP-Flury strain is one of the most attenuated RV
strains. This strain kills only suckling mice; it does not kill
adult mice, even when inoculated intracranially. Whereas
the def-P virus-infected susceptible cells at a rate equal to
that of the parental HEP-Flury strain, it did not exhibit
productive infection in any cells other than those expressing
Fig. 7. Protection of mice after lethal challenge infection, and VNA titer
after intraperitoneal immunization with P gene-deficient virus (def-P).
Groups of 6-week-old mice were injected with serial 10-fold dilutions of
def-P or parental rHEP virus or inactivated PCECV vaccine (which
corresponded to 50 Al) twice every 1-week interval. (A) One week after the
second immunization with serial 10-fold dilutions of the viruses, the mice
were infected intracranially with 50 LD50 of CVS strain and observed for 2
weeks. Survivals of mice immunized with rHEP (gray bar), def-P (white
bar), vaccine control (Vac: black bar), and non-vaccine control (Non:
shaded bar) are shown as the percentage. (B) At 6 days after the second
immunization, blood samples were obtained and VNA titers were
determined using RFFIT against HEP strain. Geometric mean titers were
normalized to International Units (IU) using the WHO standard. VNA titers
of rHEP (gray bar), def-P (open bar), and vaccine control (V: closed bar) are
shown with standard error of the mean. (C) Quantitation of N protein in the
vaccine preparations. rHEP and def-P (106 FFU), and PCECV vaccine (5
Al) (which corresponded to 1/10 of the inoculated PCECV vaccine)
preparations were subjected to SDS-PAGE and immunoblot against anti-N
antiserum.
Table 1
Survival of mice immunized with def-P or PCECV vaccine and challenged
intramuscularly with lethal rabies virus
Intramuscular vaccination witha Number of survivors/totalb
def-P 6/6
PCECV 6/6
none 0/6
Statistical analysis was done by chi-square test (P = 0.0005 between def-P
and none vaccination).
a Six-week-old mice were vaccinated intramuscularly with 106 FFU of def-
P and PCECV (0.1 ml of 1:10 dilution as a vaccine control) twice 7 weeks
apart.
b Mice were challenged with 50 IMLD50 of CVS strain after 2 weeks of
second vaccination.
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of the def-P virus did not produce clinical signs of rabies
(data not shown). In order to assess the virulence of the def-
P virus in vivo, suckling mice were intracranially inoculated
with def-P or rHEP virus, and clinical signs were monitored
(Fig. 6). Intracranial inoculation with 2  103 FFU of rHEP
caused 100% mortality in the suckling mice. In contrast, the
def-P virus did not kill the suckling mice, and did not causeany clinical signs of rabies, even after intracranial inocula-
tion with 2  104 FFU.
Induction of protective immunity in mice by P gene-deficient
virus
Although the def-P virus exhibited impaired replication
in infected cells, viral proteins were clearly expressed in the
absence of the P protein. We analyzed the def-P virus as a
vaccine candidate, using the NIH potency test. Groups of
mice were intraperitoneally immunized with different doses
of the def-P virus or the parental rHEP virus, and were then
subjected to lethal challenge with the CVS strain. Percent
survival is shown in Fig. 7A. Vaccination of mice with 106
FFU of def-P virus protected 10 of the 12 mice (83%) from
the lethal challenge, in a manner similar to that of rHEP
virus. It has been shown that virus-neutralizing antibodies
(VNA) play a major role in protection from rabies (Cox et
al., 1977; Hooper et al., 1998). VNA titers were assessed in
mice immunized with the def-P or rHEP virus (Fig. 7B).
There was a relationship between levels of VNA and dose of
inoculated virus. Immunization with 106 FFU of def-P or
rHEP induced high levels of VNA (5.61 or 2.45 IU),
resulting in effective protection (80%). The amounts of viral
proteins in the live vaccine preparation of def-P and rHEP
were compared with that in the inactivated vaccine PCECV.
RV-N protein in the inoculated virus preparations was
detected by immunoblot analysis (Fig. 7C). The amount
of N protein in 106 FFU of rHEP and def-P virus preparation
was approximately 1/10 of that in inoculated PCECV
vaccine. These results indicate that the def-P virus (at 106
FFU dose) induced high levels of VNA and suggested that
the levels of protection reflected the levels of induced
neutralizing antibodies. Another challenge experiment was
performed to analyze whether the immune response with
106 FFU of def-P was sufficient to protect the mice. After
the lethal intramuscular challenge of CVS stain, all mice
immunized with def-P survived (Table 1). These data clearly
demonstrate that immunization with 106 FFU of def-P
conferred protective immunity against a lethal rabies virus
infection.
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We succeeded in generating and propagating P gene-
deficient RV virus using an improved reverse genetics
method, complementing the functions of the P protein by
using cell lines that stably expressed viral P protein. This
recently established system does not require the presence
of T7 RNA polymerase for rescue of recombinant RV,
because primary transcription of transfected cDNA plas-
mids is driven by cellular RNA polymerase II. Using this
approach, we previously rescued RV from cDNA plasmids
in several mammalian cell lines in the absence of T7 RNA
polymerase (Inoue et al., 2003a). In the present study, to
generate the gene-deficient RV virus, cell lines constitu-
tively expressing viral P protein were established and used
as recipient cells that were directly transfected with the
genomic cDNA plasmid and helper plasmids. Using this
rescue system, we were able to generate and propagate the
P gene-deficient virus with high efficiency. Although the
genome of the def-P virus does not possess the P gene, it is
likely that in cells stably expressing P protein, the def-P
virion has a normal nucleocapsid structure including the P
protein. The present results indicate that the nucleocapsid
had viral primary transcription activity, even in cells not
expressing P protein. Analysis of growth characteristics of
the def-P virus revealed that its propagation in BHK-P
cells was moderate, compared with that of the parental
rHEP strain. The retarded growth of def-P virus was
presumably due to the low level of P protein in the
infected hosts. The amount of produced virus and the level
of viral transcription are coordinated with the amount of P
protein expression. The virus titers were 5  107 FFU in
def-P virus infection and 109 FFU in rHEP virus infection.
The level of viral transcription in def-P infection was 7–
9% of that in rHEP infection. The amount of P protein in
the cells expressing P protein was 7% of that in rHEP-
infected cells. However, we found that this retarded growth
resulted in extremely low cytotoxicity in the hosts. Thus,
multiple passages of cultures infected with def-P virus
allowed continuous propagation of progeny viruses for a
long period.
The def-P virus was able to infect mammalian cells in
the same manner as the parental HEP-Flury strain was. The
def-P virus was, however, able to propagate only in an
environment in which P protein was provided by the
infected hosts. The viral polymerase complexes, which
had been incorporated in the def-P virus particle, were
able to transcribe viral messenger RNA in BHK cells
without de novo synthesis of the P protein (Fig. 5).
However, almost no egress of infectious progeny was
observed in the def-P virus-infected BHK cell cultures
(Fig. 4B). The viral RNA replication requires the encapsi-
dation of viral RNA with nascent N protein, followed by
synthesis of large amounts of N protein (Benerjee and
Barik, 1992; Patton et al., 1984). Therefore, the def-P virus
can hardly replicate the viral RNA genome and hardlyproduce progeny virus unless P protein is supplied. Further
characterization of the def-P virus can provide insight into
the function of viral RNA polymerase and the structure of
the RV ribonucleocapsid.
Analysis of pathogenicity of the def-P virus indicated
that it was completely apathogenic in mice. This apathoge-
nicity can be attributed to impaired replication in the
infected hosts. It is unlikely that residual pathogenicity
occurred in any of the inoculated animals. The def-P virus
lacks the gene in the P protein-encoding region. Acquisition
of the gene due to genetic mutation is ruled out. Therefore,
reversion to virulence is completely ruled out. On the other
hand, expression of viral antigens was clearly observed in
the infected cells. We also found that the def-P virus elicited
high levels of protective immunity; thus, the def-P virus
may be useful in development of safe live vaccine against
rabies. Intraperitoneal immunization of mice with 106 FFU
of def-P elicited protective immunity against the lethal
challenge. The vaccine efficacy of def-P was similar to that
of the parental rHEP strain. The def-P virus induced virus-
neutralizing antibodies in a dose-dependent manner. Al-
though inoculation of mice with 105 FFU of def-P or rHEP
induced relatively high levels of VNA, it conferred only
incomplete protection. It is likely that VNA levels induced
by these viruses were required to be greater than 2.0 IU to
confer highly effective protection of mice against an intra-
cranial challenge with CVS. In the challenge experiments, a
heterologous strain was used in accordance with the NIH
protocol. Previous findings indicate that protection is greater
when a homologous virus is used for the lethal challenge
(Barth et al., 1988; Morimoto et al., 2001).
In our experiments, intraperitoneal and intramuscular
immunization twice with 106 FFU of def-P virus conferred
the protective immunity. Further investigations will be
directed whether the primer-boost vaccination is necessary
or not to achieve the efficacy. Assessments of different
administration routes and the duration of immunity stimu-
lated by def-P improve understanding of the efficacy of the
def-P virus-based vaccine, and can expand the application
range of the def-P virus-based vaccine. Oral vaccination of
wild animals against rabies is the most convenient and
effective method for controlling rabies. Propagation of RV
in mucosal membrane is necessary for induction of protec-
tive immunity (Morimoto et al., 2001). In the future, we will
examine the possibility of using the def-P vaccine for oral
vaccination.
In contrast to inactivated vaccine, a live attenuated
vaccine has the advantages of strong induction of cytotoxic
T-lymphocyte (CTL)-mediated immune response (Seder
and Hill, 2000). Inactivated vaccine does not elicit a
cytotoxic T cell response. We speculate that the def-P virus
elicits both a cytotoxic T cell response and a humoral
immune response. We also speculate that the live def-P
vaccine induces long-lasting protective immunity. Previous
findings suggest that the strength of the immune response
is regulated by the amount of antigen expressed (Bukreyev
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enhancing the efficacy of def-P virus-based vaccine by
manipulating the def-P virus genome using reverse genet-
ics. It has been shown that insertion of an immune-
stimulating cytokine gene (e.g., granulocyte–macrophage
colony-stimulating factor: GM-CSF) can enhance the effi-
cacy of parainfluenza vaccine and DNA vaccine (Bukreyev
et al., 2002; Pasquini et al., 1997; Xiang and Ertl, 1995). It
has been reported that integration of a proapoptotic gene
(e.g., cytochrome c) or an extra RV-G gene into the
genome of an attenuated RV-based vector improves its
vaccine efficacy (Faber et al., 2002; Pulmanausahakul et
al., 2001). We are currently trying to generate def-P
recombinants containing foreign genes. We speculate that
a live def-P recombinant expressing G protein derived from
RV circulating in rabies-endemic areas would be promising
as a more effective and safer vaccine against the endemic
rabies. The present reverse genetics system can be used to
efficiently generate and propagate RV mutants lacking
genes other than the P gene. Previous findings suggest that
M gene-deficient RV is replication-competent in infected
hosts, although release of progeny viruses is reduced by
500000-fold due to severe impairment of particle formation
(Mebatsion et al., 1999). We are currently working to
generate an M gene-deficient virus and examine its vaccine
efficacy.Materials and methods
Cells and viruses
Neuroblastoma NA cells of A/J mouse origin were
grown at 37 jC in minimum essential medium (MEM)
supplemented with 10% heat-inactivated fetal bovine se-
rum (FBS). BHK-21 cells were grown at 37 jC in
Dulbecco’s modified Eagle’s medium (D-MEM) supple-
mented with 10% FBS. To establish a cell line constitu-
tively expressing the P protein, NA and BHK-21 cells
were transfected with pH-P plasmid (eukaryotic expression
vector, pcDNA3.1/Zeo [Invitrogen, USA], containing P
gene cDNA); the construct is described elsewhere (Inoue
et al., 2003a). The transfected cells were selected accord-
ing to Zeocin (Invitrogen) resistance for several weeks.
The resistant cells were cloned and examined for expres-
sion of the P protein by immunofluorescence staining
with anti-P antiserum. The NA and BHK cell lines ex-
pressing the P protein were designated NA-P and BHK-P,
respectively.
A cDNA-derived RV (rHEP) was generated from full-
length cDNA of HEP-Flury strain (Japanese rabies vaccine
used to vaccinate humans), using an improved cDNA
recovery method (Inoue et al., 2003a). The rHEP strain
was used for parental control strain. A P gene-deficient virus
(def-P) was recovered from full-length cDNA lacking the P
gene, as described below.Production of monospecific antiserum against RV P or N
protein
A cDNA encoding the complete P protein of CVS-11
strain was inserted into the bacterial expression vector
pQE-9 (QIAGEN, Japan). Prokaryotic His-tagged recom-
binant P protein (rP) was expressed and purified accord-
ing to the manufacturer’s instructions. The purified rP
protein was emulsified with complete Freund’s adjuvant
(Difco Laboratories, USA) and was subcutaneously
injected into female Japanese white rabbits (KBL Inc.,
Japan). After triple booster immunizations with rP protein
mixed with incomplete Freund’s adjuvant (Difco Labo-
ratories), immune sera were collected from the rabbits
and purified. Specificity was confirmed by immunoblot
analysis with rabies viral proteins. Preparation of rabbit
anti-N antiserum was previously described (Inoue et al.,
2003b).
Plasmid construction of P gene-deficient full-length cDNA
The sequence of the full-length cDNA of the recombi-
nant HEP-Flury strain has been deposited in the GenBank
database (accession no. AB085828). Construction of the
full-length cDNA vector (pHEP-3.0) is described elsewhere
(Inoue et al., 2003a). Briefly, the full-length cDNA se-
quence was flanked by two ribozyme cDNAs, generating
authentic 5V and 3V ends of the full-length viral RNA
transcript, which was under the control of the human
cytomegalovirus (CMV) promoter. In the first step of
constructing P gene-deficient cDNA (Fig. 1A), a PCR
fragment was amplified using the following primers: H-
Avr5 (near the AvrII site of the N gene), 5V-TATAACCCC-
TAGGGAAAGCCC-3V (AvrII site underlined); Nstop-Blp3
(introduces a BlpI site behind the stop codon of the N gene),
5V-GTCGCTTAGCTCCTTAGAGTCACTCG-3V (BlpI site
and stop codon underlined). To remove the region encoding
the P protein, this PCR fragment was inserted into pHEP-
3.0 plasmid that had previously been digested with AvrII
and BlpI. The resulting plasmid was designated p3.1-defP
(Fig. 1A).
Recovery of rabies virus from cDNA plasmid
The recombinant virus was rescued as described else-
where (Inoue et al., 2003a). BHK-P cells constitutively
expressing P protein were used as transfected recipient
cells in rescue of the defective virus. Briefly, the BHK-P
cells were grown overnight to 80% confluency (around 4
to 6  105 cells per well) in 6-well culture plates in D-
MEM supplemented with 10% FBS. Culture supernatants
were replaced with fresh medium before transfection. The
cells were transfected with 2.0 Ag of p3.1-defP plasmid,
0.5 Ag of pH-N, 0.25 Ag of pH-P, 0.1 Ag of pH-L, and
0.15 Ag of pH-G (pH-N, pH-P, pH-L, and pH-G are
helper plasmids that express viral N, P, L, and G proteins
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(Panvera, Madison, WI). Although transfection with pH-
G plasmid was not necessary for generation of rescued
virus, the supply of G protein occasionally improved
yield of the virus (Inoue et al., 2003a; Morimoto et al.,
2000, 2001). After 16–24 h, the cells were washed once
and maintained in D-MEM supplemented with 10% FBS
for a further 2–5 days. The culture supernatant was
transferred onto BHK-P cell monolayers and incubated
for 3 days at 34 jC. The culture supernatant was
harvested and titrated for preparation of virus stock for
further experiments. The rescued virus generated from the
full-length P-deficient plasmid p3.1-defP was designated
def-P virus. Nucleotide sequence analysis confirmed that
the genome of def-P virus lacked the P gene, and
indicated that the rescued virus was faithfully derived
from the cDNA of p3.1-defP (data not shown).
Immunofluorescence staining and virus titration
The BHK-P cells were used to assay for presence of
rescued virus by immunofluorescence using fluorescein
isothiocyanate (FITC)-labeled RV N protein-specific anti-
body (Centcor Inc. Malvern, PA). Monolayers of BHK-P
cells in 96-well plates were infected with serial 10-fold
dilutions of virus suspension and incubated at 34 jC, as
described elsewhere (Wiktor et al., 1984). At 48-h postin-
fection, the cells were fixed with 80% acetone and stained
with FITC-labeled RV N protein-specific antibody. Foci
were counted under a fluorescence microscope and calcu-
lated as focus-forming units per milliliter (FFU/ml). All
titrations were performed in triplicate, and the average was
used as the virus titer.
Immunoblot analysis
Cells were lysed with IP buffer (1% Triton X-100, 1%
deoxycholate, 10 mM Tris–HCl, 150 mM NaCl with
protease inhibitor cocktail tablet [complete, mini, EDTA-
free, Roche Diagnostic]) and the nuclei were removed by
low speed centrifugation. The same amount of the double-
concentrated lysis buffer for SDS-PAGE was added to
each lysate. Diluted PCECV vaccine preparation and 106
FFU of rHEP or def-P virus suspension were added with
same amount of the double-concentrated lysis buffer for
SDS-PAGE. The SDS-PAGE samples were subjected to
precast 10% gel SDS-PAGE (ATTO Co., Japan). The
proteins separated in the gel were blotted onto the
nitrocellulose membrane filter by semidry method. The
filter was then incubated with the anti-P or anti-N antise-
rum as the first antibody, and then with the alkaline
phosphatase-conjugated anti-rabbit IgG as the second
antibody. Color was developed by Western Blue Stabilized
Substrate for Alkaline Phosphatase (Promega). The col-
ored bands were quantitated by densitometry with the NIH
Image program.RNA extraction and RT-PCR amplification
To determine the amounts of viral transcripts in the def-P
virus-infected BHK and BHK-P cells, messenger RNA of
virus-infected cells was amplified with RT-PCR. Total RNA
was extracted from the virus-infected cells using ISOGEN
(Nippon gene, Japan) according to the manufacturer’s pro-
tocol. Reverse transcriptase (RTase) reactions were per-
formed at 42 jC for 1 h with avian myeloblastosis virus
RTase (Takara Biomedicals, Japan) and an oligo-(dT) primer.
Rabies virus N, P, and G genes, and the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene (internal control
of RNA preparations), were amplified with the following
primer sets: N sense primer (N5-a: 5V-ATGGATGCCGA-
CAAGATTGT-3V) and N antisense primer (N3-a: 5V-CCC-
ACTCTGATTGCCGAATA-3V); P sense primer (HP-start5:
5V-TTGGTACCATCCCAAGTATGA-3V) and P antisense
pr imer (HP-Bpu3: 5 V-TCTTGCATGATTTTGCT-
TAGCTTGTC-3V); G sense primer (C5-a: 5V-CTTCACT-
CAAGGGTCTTC-3V) and G antisense primer (C3-a: 5V-
GGAGGTGAACTTCAACAA-3V); GAPDH sense primer
(5V-TGCCAAGGCTGTGGGCAAGGTCAT-3V) and GAPDH
antisense pr imer (5 V-AACAGGGTGGTGGACCT-
CATGGCC-3V). The estimated fragment sizes of N, P, G,
and GAPDH were 684, 882, 816, and 348 bases, respective-
ly. To examine the genomic RNA contamination in RT
preparation, the intragenic region was amplified with NS5-
1 primer (5V-TTCCAATCATCAAGCCCGTC-3V) and M3-b
primer (5V-GTAAAGGTTATCAACTTGAC-3V). The frag-
ment size of def-P virus was 972 bases.
Pathogenicity in suckling mice
Groups of 10 suckling ICR mice (Japan SLC. Inc.,
Japan) were infected intracranially with 20 Al of virus
dilution. After the infection, the mice were observed daily
for 2 weeks.
Immunization and virus challenge
The vaccine potency test was performed according to
the NIH standard protocol (Wilbur and Aubert, 1996).
Groups of 6-week-old female ICR mice (Japan SLC.
Inc., Japan) were inoculated intraperitoneally with 0.5 ml
of serial 1:10 dilutions of live rHEP or def-P virus, twice
with a 1-week interval. As a control vaccine preparation,
the Japanese purified chick embryo cell culture rabies
vaccine (PCECV) (Chemo-Sero-Therapeutic Research In-
stitute, Japan) was injected with 0.5 ml of the 1:10 dilution
(which corresponded to 50 Al of PCECV vaccine). Two
weeks after the first vaccination, the mice were intracrani-
ally challenged with a 30-Al injection containing 50
ICLD50 (median intracranial lethal dose) of CVS strain,
and observed for 2 weeks for development of clinical
signs. At 1 day before the challenge infection, the vacci-
nated mice were eye-bled, and the sera were subjected to
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challenge experiments, groups of six 6-week-old female
ICR mice were immunized intramuscularly in the hind leg
twice, 7 weeks apart, with 0.1 ml of 106 FFU of live def-P
virus. As a control vaccine group, mice were injected with
0.1 ml of the 1:10 diluted PCECV rabies vaccine. Two
weeks after the second vaccination, the mice were intra-
muscularly challenged with a 0.1-ml injection containing
50 IMLD50 (median intramuscular lethal dose) of CVS
strain, and observed for 4 weeks for development of
clinical signs.
Titration of virus-neutralizing antibody
Mice were eye-bled after the inoculation. Usually, not
more than 50 Al of blood was collected from each mouse.
Mouse sera were serially fourfold diluted, starting from a
dilution of 1:10, and tested for neutralizing antibody using
the rapid fluorescent focus inhibition test (RFFIT), as
described elsewhere (Wiktor et al., 1984). Neutralizing
antibody titers, defined as the highest serum dilution that
neutralizes 50% of the challenge virus (HEP-Flury strain),
were normalized to international units (IU) using the World
Health Organization (WHO) anti-RV antibody standard.
Geometric mean titers (GMT) were calculated from the
titers of six mice.Acknowledgments
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